LABS and MEDIF Related Headlines
Go Back- MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
- MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
- MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
- MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
- Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
- MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
- MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
LABS and MEDIF Related Press Releases
Go Back- MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
- MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
- MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
- MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
- Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
- MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis
- MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
